MG (@mg10012) header
MG (@mg10012) profile picture

Fan of Wyeth. Investor motivated by Information Theory and ideas of Claude Shannon. Professional Infovore. Nothing I say or write is investment advice.

New York, USA
Joined January 2009
Photo by MG (@mg10012)Photo by MG (@mg10012)Photo by MG (@mg10012)Photo by MG (@mg10012)Photo by MG (@mg10012)Photo by MG (@mg10012)Photo by MG (@mg10012)Photo by MG (@mg10012)Photo by MG (@mg10012)
This press release from $BEAM confirms what the NEJM article in the tweet signaled: the FDA is fundamentally changing how it evaluates gene therapies for classic genetic (monogenic) diseases. FDA alignment on accelerated approval for BEAM-302 in AADT (lung & liver disease) based on biomarker endpoints over 12 months, not years of clinical outcome data. This is the plausible mechanism pathway in action. When you have a clear genetic mutation causing a measurable protein deficiency, and your therapy demonstrably corrects that deficiency, the FDA will now accept mechanistic proof rather than demanding traditional Phase 3 trials. Stock is up ~25% today, ~150% from April lows. I bought a slug between $20 and $23 last year, and am taking 1/3 off (my usual plan). The real catalysts remain ahead: risto-cel BLA expected year-end 2026, BEAM-302 pivotal data by end of Q1 2026. The move reflects de-risked regulatory pathway, not actual approval. More important than BEAM itself: this validates the broader sector thesis. Companies targeting monogenic diseases with clear genotype+phenotype relationships now face fundamentally different risk/reward profiles than those pursuing complex conditions. The regulatory bar has shifted. investors.beamtx.com/news-re…
This short article from the NEJM (one of the premier medical journals) by 2 FDA officials has been referenced by folks on X: nejm.org/doi/pdf/10.1056/NEJ… The investment implications of this memo are potentially profound. The FDA officials have unveiled a transformative regulatory framework that would eliminate randomized controlled trial requirements for gene therapies targeting clear genetic disorders. The article outlines how therapies can gain approval based on mechanistic coherence and patient outcomes rather than statistical significance. This only applies to diseases with unambiguous genetic causation - where specific mutations directly cause disease through known biological mechanisms. When companies demonstrate successful genetic correction and meaningful clinical improvement in just "several consecutive patients," the FDA will grant platform approval covering all such mutations. This replaces the traditional requirement for separate trials for each variant. The investment implications are profound. Development costs could drop from > $100mm+ to 10% of that. Approval timelines would also shrink from 10+ years to potentially 2-3 years. Probability of success increases dramatically for companies with clear mechanistic targets. NOTE: there are no advantages for companies pursuing diseases with complex or no genetic causes. Natural history data for the disease will suffice as opposed to actual controls. Instead, if science knows that gene X mutation -> loss of protein Y -> disease Z and your therapy restores protein Y function and patients improve dramatically, that's sufficient evidence. You don't need statistics to prove that fixing the root cause fixes the disease—the biology itself is the proof. This creates immediate valuation disparities. Companies with platform technologies addressing monogenic diseases -- sickle cell, muscular dystrophy, inherited blindness, rare metabolic disorders -- now face fundamentally different risk profiles than those targeting complex conditions like Alzheimer's or diabetes. $PRME, $BEAM, $CRSP, $NTLA, $SRPT
2
9
4,540
This short article from the NEJM (one of the premier medical journals) by 2 FDA officials has been referenced by folks on X: nejm.org/doi/pdf/10.1056/NEJ… The investment implications of this memo are potentially profound. The FDA officials have unveiled a transformative regulatory framework that would eliminate randomized controlled trial requirements for gene therapies targeting clear genetic disorders. The article outlines how therapies can gain approval based on mechanistic coherence and patient outcomes rather than statistical significance. This only applies to diseases with unambiguous genetic causation - where specific mutations directly cause disease through known biological mechanisms. When companies demonstrate successful genetic correction and meaningful clinical improvement in just "several consecutive patients," the FDA will grant platform approval covering all such mutations. This replaces the traditional requirement for separate trials for each variant. The investment implications are profound. Development costs could drop from > $100mm+ to 10% of that. Approval timelines would also shrink from 10+ years to potentially 2-3 years. Probability of success increases dramatically for companies with clear mechanistic targets. NOTE: there are no advantages for companies pursuing diseases with complex or no genetic causes. Natural history data for the disease will suffice as opposed to actual controls. Instead, if science knows that gene X mutation -> loss of protein Y -> disease Z and your therapy restores protein Y function and patients improve dramatically, that's sufficient evidence. You don't need statistics to prove that fixing the root cause fixes the disease—the biology itself is the proof. This creates immediate valuation disparities. Companies with platform technologies addressing monogenic diseases -- sickle cell, muscular dystrophy, inherited blindness, rare metabolic disorders -- now face fundamentally different risk profiles than those targeting complex conditions like Alzheimer's or diabetes. $PRME, $BEAM, $CRSP, $NTLA, $SRPT
1
8
6,463
Thoughts on $VKTX: Viking's Ph2 oral VK2735 data creates a clear, high-beta investment thesis: a drug with a potentially best-in-class efficacy profile that now faces a quantifiable execution risk on patient tolerance. The market punished the stock, creating an opportunity for LT capital. The Ph2 results are clear: drug's efficacy is pretty solid. It delivered up to 12.2% mean weight loss in just 13 weeks. To put that in perspective, Eli Lilly's ($LLY) oral orforglipron took 26 weeks in its Phase 2 to achieve a similar 12.6% and 72 weeks in its Phase 3 to hit 12.4%. This superior speed and slope, likely driven by its dual GLP-1 + GIP mechanism, is a powerful advantage. This efficacy comes at a cost. The trial saw high rates of GI side effects and a 28% overall discontinuation rate in the drug over 13 weeks. However, context is crucial here. 99% of GI-related adverse events were mild or moderate, and their frequency declined significantly after the 3rd week of treatment. The high 48% placebo nausea rate also suggests a significant "nocebo" effect in the current trial environment (this is the reverse placebo where folks' knowledge and expectation of AEs with GLP-1s may "cause" AEs). What the market might not be counting: VKTX discovered something potentially novel -- patients can be induced at 90mg then maintained at 30mg while preserving or even improving weight loss (9.2% at week 13). This is a re-conceptualization of obesity treatment that Lilly hasn't explored. Combined with VK2735's 8 day half-life enabling potential weekly oral dosing, Viking has uncovered treatment paradigms unavailable to competitors. Net-net: VKTX's oral drug just did what a good Phase 2 should do: it proved the pharma science with an unusually steep early slope (~11-12% mean weight loss at 13 weeks at top doses, placebo-adjusted ≈11%) and it mapped the therapeutic window -- including a credible induce & maintain strategy (rapid initial dose to 90 mg, then 30 mg maintenance resulting in 9% weight loss at week 13). That is a real drug signal, not marketing. The catch is tolerability: doctors will prescribe the drug because of the efficacy, patients (i.e. customers) will keep taking the drug because of the tolerability.  That's what can make a potential commercial blockbuster. The bet now is whether or not VKTX can execute and design a Ph2B and Ph3 that optimizes this data dump. Disclosure: I am long here (not financial advice).
12
18
5
113
21,149
Professor @JohnHCochrane. I am persuaded by your FTPL, so I am reaching out for your take on current macro news. OBBB widens the primary budget gap by ~$350 B/yr atop a baseline already near $2 T, yet Treasury funding is increasingly via 1Y and 2Y paper. If rumors are true that Trump wants to fire Powell and install Treasury‑friendly chair that would lower rates and caps yields, unexpected inflation must do all the adjusting because bond prices cannot.  With 1/3 of debt rolling every 12 months, does a sustained move or a single discrete jump to 5 % inflation seem plausible given my back of the envelope math using FTPL? If the above events (OBBB + lower duration Treasuries + new Fed chair) come to pass, is there anyway inflation stays low except for Congress cutting spending somehow? Grateful for any insight.
3
21
4,378
Happy birthday, America! 🇺🇸🇺🇸🇺🇸 For those interested: archives.gov/founding-docs/d…
1
2
16
2,811
The Hoover Institution had a panel on the Trump tariff policy. hoover.org/events/panel-tari…. I thought it was very interesting, and it seemed to corroborate much of what I and @wabuffo had been stating in the hours and days after these were first announced. Bear with me, I'm going to get a little long winded here. Redding regurgitated the textbook argument that cross-border trade benefits a country's consumption in the same way that a technology improvement would. By raising prices on imports, tariffs reduce those gains and generate "dead weight loss" (the b+d in his diagram). He calculates that the 2018 tariff case generated about $15B of tariffs but about $8 billion of dead weight loss. This is likely to be much higher because the dead weight increases quadratically with the tariff rate, which is much higher this go around. Also, modern tariffs are much more destructive because of the global supply chains. A imported good that is "protected" and has tariffs levied on it is often an input for another domestic industry. Redding relates the 2018-19 metals tariffs to declines in factory employment and output. Davis moves the discussion to policy uncertainty and the volatility that results from it. He has created a trade policy index that has spiked from this latest news --orders of magnitude higher than the long-term average since 1945. We've seen huge daily vol in the S&P and the VIX had several high episodes this month. Davis' presentation also references a 4% drop in job openings from LinkUp in the 2 weeks bracketing the "Liberation Day" speech. His claim is easy to validate -- policy uncertainty itself is a negative macro shock to GDP. If we invoke the "real options" approach to analyzing investment, from economists Dixit and Pindyck, this extra policy volatility should result in a substantial reduction in new investment and hiring. Because capital outlays are "irreversible", higher volatility on future profitability levels raises the value of waiting and pushes hurdle rates upward without any increase in the risk-free rate. The result is a sudden stop in discretionary capex and a near-term hiring freeze. This is what I expect to see if the current environment persists. We should see this in the aggregate data in the next 2 quarters. Bordo & Levy give a little historical color to the argument. The effective tariff on Chinese imports would rise to over 130%, lifting the weighted average tariff above Smoot Hawley levels. Since tariffs are a rounding error on federal receipts, the programme will result in an even bigger fiscal deficit. Also, the 180 turn on previous trade commitments puts at risk the broader expectation that the US honors its international contracts. This could result in a credibility crisis in the Treasury market (perhaps why gold is going up). That credibility premium feeds back into our "real options" analysis by increasing the discount rate -- moving the investment hurdle rate even higher. Bordo & Levy think that probability of recession is 70% even if escalation halts at current levels and they handicap a full blown depression at about 5%. In every scenario, the combo of higher discount rates and higher volatility in cash flows depresses private capital formation for years, not quarters. I personally am not as pessimistic as these guys, but I am moving in that direction. The signals from the equity market suggest something else. I will be watching non-residential investment and net hiring, because if this theory is correct, we should see a noticeable slowdown by mid summer. This is because the real options hurdle will shift the calculation for all new investment. Unless the administration caps tariff rates and articulates a clear exit strategy, the uncertainty component alone will continue to sap potential output, and the US will find itself trading strategic leverage today for a structurally smaller capital stock tomorrow. Ironically, this is the opposite of what the MAGA movement wants.
5
8
42
5,253
Happy New Year to my Persian and Afghan friends and all others celebrating! نوروز شد و لاله‌ی خوش‌رنگ برآمد مردم به تماشا‌ی گل و سنگ برآمد مرغان هوا بال گشودند به یک‌ بار و مرغ دلکم از قفس تنگ برآمد
16
2,416
Merry Christmas to all who are celebrating. “Adoration of the Shephards” by Caravaggio
2
1
26
2,616
Join @161phi and I to chat about random stuff taken from various things we read. If you have finished your holiday parties and shopping for the day, bring an article that you want to read and discuss. teapaw.org/i/spaces/1lDGLloDvvRGm

2
7
1,978
Happy Thanksgiving to all.
1
14
9,018